Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0654 • ACR Convergence 2025
Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Ed Vital¹, Benni Vargas², Julie Rae², Tracey Wang³, Jason Hackney², Cary Looney⁴, William Pendergraft², Liz Lightstone⁵, Brad Rovin⁶, Richard Furie⁷ and Harini Raghu², ¹University of Leeds, Leeds, England, United Kingdom, ²Genentech, Inc., South San Francisco, CA, ³Hoffmann-La Roche Ltd, Missssauga, ON, Canada, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁶The Ohio State University, Columbus, OH, ⁷Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation. B cells play a central role in LN pathogenesis and type I interferon (IFN-I) pathway activation…
Abstract Number: 1195 • ACR Convergence 2025
Discordance between Immunoblot and ELISA in the detection of Jo-1 and Ro/Ro-52 Autoantibodies
Antonia Valenzuela¹, Sebastián Andrés Cerda Acevedo² and Francisco Vera Gutiérrez², ¹Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Pontificia Universidad Católica de Chile, Santiago de Chile, Chile
Background/Purpose: Autoantibodies play a key role in the diagnosis, classification, and prognosis of idiopathic inflammatory myopathies (IIM). Among the most relevant are myositis-specific antibodies (MSAs),…
Abstract Number: 1693 • ACR Convergence 2025
Characterizing ANCA-specific B Cells in ANCA-associated Vasculitis
Laura van Dam¹, Mengrui Zhang¹, Shima Parsafar², Audra Horomanski³, Sajede Rasouli², Orr Sharpe², Jolijn van Leeuwen⁴, Tobias Lanz², Cees van Kooten⁴, Onno Teng⁵ and William H. Robinson³, ¹Stanford University, Stanford, CA, ²Stanford University, Stanford, ³Stanford University, Palo Alto, CA, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Leiden University Medical Center, Leiderdorp, Netherlands
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a severe autoimmune disease, characterized by ANCAs targeting myeloperoxidase (MPO) or proteinase-3 (PR3). ANCA-specific B cells have…
Abstract Number: 2103 • ACR Convergence 2025
PCRX-201 High-Capacity Adenovirus Serotype 5 Gene Therapy Demonstrates Sustained Clinical Efficacy and Safety in Patients With Knee Osteoarthritis
Stanley Cohen¹, Philip Conaghan², Marc C. Hochberg³, Alan Kivitz⁴, MiJeong Kim⁵, Nino Joy⁶, Shoshanna Jiang⁶, Mary DiGiorgi⁷, Jonathan Slonin⁶ and Derek Slonin⁶, ¹Metroplex Clinical Research Center, dallas, TX, ²University of Leeds, Leeds, United Kingdom, ³Marc C. Hochberg University of Maryland School of Medicine, Baltimore, MD, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Pacira BioSciences, Inc., Brisbane, ⁶Pacira BioSciences, Inc., Brisbane, CA, ⁷Pacira BioSciences, Inc, Brisbane, CA
Background/Purpose: Knee OA is a common disease affecting ~15 million people in the United States. There is an urgent unmet need for additional OA treatments…
Abstract Number: 2484 • ACR Convergence 2025
Phenotype of systemic sclerosis patients with positive anti–NOR-90 antibodies
Javier Narváez¹, Santos Castañeda², Montserrat Roig Kim³, Martí Aguilar-Coll⁴, Laia De Daniel Bisbe³, Marina Dueñas⁵, Cristina Valero⁶, Francisco Morandeira⁷, Miguel A. González-Gay⁸ and Joan Miquel Nolla³, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ³Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Department of Rheumatology.Hospital Universitario de la Princesa, Madrid, Spain, ⁶Hospital de la Princesa, Madrid, Spain, ⁷Department of Immunology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: To analyze the clinical associations of anti-Nucleolar Organizer Region 90 antibodies (NOR90) antibodies in patients with systemic sclerosis (SSc)Methods: Cross-sectional study of NOR90-positive SSc…
Abstract Number: 0137 • ACR Convergence 2025
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
RITESH KUMAR MISHRA¹, SUBIN PHILIP², JAIDEV MENON², RIZWANA NAUSHAD², AISHWARYA GOPAL³, CHRISTINA MARIASELVAM², Chengappa Kavadichanda², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Primary Antiphospholipid Syndrome (APS) a systemic autoimmune prothrombotic disorder with long-term consequences. While secondary APS is well studied, large real-world cohorts of primary APS…
Abstract Number: 0513 • ACR Convergence 2025
Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies
Massiel Jimenez Artiles¹, asim Khanfar², Pratibha Chaudhary³, Roshan Subedi⁴, Qi Wang⁵ and Anthony Ocon⁶, ¹Rhode Island Hospital, North Providence, RI, ²Rochester Regional Health, Rochester, NY, ³Rochester General Hospital, Rochester, NY, ⁴Medstar Washington Hospital Center, Washington, DC, ⁵Metrohealth System/Case Western Reserve University, Cleveland, OH, ⁶Rochester Regional Health, Fairport, NY
Background/Purpose: While Sjögren’s disease is commonly associated with anti-SSA (anti-Ro) and/or anti-SSB (anti-La) antibodies, these autoantibodies are not disease-specific and may be present in various…
Abstract Number: 0694 • ACR Convergence 2025
Treatment of Sjögren’s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod
isabelle peene¹, Gwenny Verstappen², Joke Deprez³, Frans Kroese², Suzanne Arends², Andrew Kelly⁴, Lana Vandersarren⁵, Edward Bowen⁶, Julie Jacobs⁷, Paul Meyvisch⁸, Dirk Elewaut⁹ and Hendrika Bootsma¹⁰, ¹University Hospital Ghent, Ghent, Belgium, ²University Medical Center Groningen, Groningen, Netherlands, ³Ghent University, Ghent, Belgium, ⁴Argenx, Philadelphia, PA, ⁵Argenx, Boston, MA, ⁶IQVIA, Stevenage, United Kingdom, ⁷argenx, Ravels, Belgium, ⁸argenx, Ghent, Belgium, ⁹VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ¹⁰UMCG, Groningen, Netherlands
Background/Purpose: Background/Purpose Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration and progressive, immune-mediated dysfunction of the exocrine glands. Immunoglobulin (Ig)…
Abstract Number: 1197 • ACR Convergence 2025
Genetic Profiling of Idiopathic Inflammatory Myopathies in Indian Patients Reveals Genotype-Phenotype Correlation
Bandana Jassal¹, Aishwarya Dhall¹, Mohammed Faruq², Danveer Bhadu¹, Uma Kumar¹ and Mehar Chand Sharma¹, ¹All India Institute of Medical Sciences, New Delhi, New Delhi, Delhi, India, ²Institute of Genomics and Integrative Biology, New Delhi, Delhi, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune muscle disorders with complex genetic underpinnings. Most genetic studies have focused on limited populations. This study explores…
Abstract Number: 1706 • ACR Convergence 2025
Overcoming Barriers to ANA Testing in Pediatric Populations in Africa
Ekemini Ogbu¹, Angela Migowa², Rashmi Sahay¹, Dhriti Sharma¹, Patricia Vega-Fernandez¹, Michael Henrickson¹, Evans Omalla³, Ayodele Faleye⁴, Wafa Hamdi⁵ and Hermine Brunner¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Aga Khan University Medical College East Africa, Nairobi, Kenya, ³Pediatric Society of the African League Against Rheumatism, Nairobi, Kenya, ⁴Lagos state university teaching hospital Ikeja, Lagos, Lagos, Nigeria, ⁵Kassab Institute, Faculty of Medicine of Tunis UR¹⁷SP⁰⁴, Tunis El Manar Univeristy, MANOUBA, Tunisia
Background/Purpose: Timely diagnosis of children, adolescents and young adults with rheumatologic disorders remains a global challenge especially in lower resource countries and areas (LRCs). There…
Abstract Number: 2148 • ACR Convergence 2025
Initial MRI Findings as Predictors of Disease Phenotype in Juvenile Dermatomyositis: A Comparative Study of Myositis Specific Antibodies NXP2-Positive and Myositis Specific Antibody-Negative Patients in a Large Tertiary Hospital
Juan Torres Sanchez¹, Pritish Bawa², Andrea Ramirez¹, MaiLan Nguyen³, Amit Thakral⁴, Xiaofan Huang¹, J Herman Kan² and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Texas Childrens Hospital, Houston, TX, ³Baylor College of Medicine, Austin, TX, ⁴Texas Children’s Hospital, Houston, TX
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy of childhood, characterized by proximal muscle weakness and distinctive cutaneous findings. Magnetic resonance imaging…
Abstract Number: 2491 • ACR Convergence 2025
High Prevalence of Autoimmunity and Cancer in Anti-NOR90-positive Patients: A Multicenter Observational Study
Marina Dueñas-Ochoa¹, Cristina Valero², Francisco Morandeira³, Juan Carlos Sáez¹, Maryia Nikitsina⁴, Montserrat Roig Kim⁵, Laia De Daniel Bisbe⁵, Esther Vicente-Rabaneda⁶, Arantza Alfranca¹, Miguel A. González-Gay⁷, Martí Aguilar Coll⁸, Rosario Garcia Vicuña⁶, Javier Narváez⁹ and Santos Castañeda¹⁰, ¹Hospital La Princesa, Madrid, Spain, ²Hospital de la Princesa, Madrid, Spain, ³Department of Immunology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, ⁵Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁶Hospital Universitario de La Princesa, Madrid, Spain, ⁷Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, ⁸Hospital Bellvitge, Barcelona, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Anti-Nucleolar Organizer Region 90 (anti-NOR90) antibodies target nucleolar proteins involved in ribosomal RNA transcription and processing, key steps in protein synthesis. These antibodies have…
Abstract Number: 0139 • ACR Convergence 2025
When One Isn’t Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?
Santiago Dans Caballero¹, Massimo Radin², Chary López pedrera³, MARIA ANGELES AGUIRRE ZAMORANO⁴, Christian Merlo-Ruiz⁵, Ismael Sanchez-Pareja⁴, Irene Cecchi⁶ and Savino Sciascia⁷, ¹Reina Sofia University Hospital, Lebrija, Andalucia, Spain, ²University of Turin, Turin, Turin, Italy, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁶University of Turin, Turin, Piemonte, Italy, ⁷University of Turin, Torino, Italy
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the persistent presence of antiphospholipid antibodies (aPL) along with clinical manifestations such as venous…
Abstract Number: 0529 • ACR Convergence 2025
Anti-PeptidylArginine Deiminase-2 (anti-PAD2) Autoantibodies in Psoriatic Arthritis
Ana-Maria Orbai¹, Hong Wang², Maria Grecu³, Ning Meng⁴, Ji Soo Kim⁵, Clifton Bingham⁴, Uzma Haque², John Miller⁴, Felipe Andrade², Erika Darrah⁶ and Eleni Tiniakou⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³River Hill High School, Clarksville, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD, ⁶Astra Zeneca, Gaithersburg, MD, ⁷UT Health Science Houston, Houston, TX
Background/Purpose: Citrullinated cathelicidin (LL37), a human-derived antimicrobial peptide, is an autoantigen in psoriatic arthritis (PsA).1 LL37 citrullination by peptidylarginine deiminase (PAD) enzymes attenuates immune activation…
Abstract Number: 0701 • ACR Convergence 2025
Exploring Calcinosis On Hand X-Rays In Systemic Sclerosis: a Mayo Clinic Cohort
Maximiliano Diaz Menindez¹, Simran Ravindra Nimal², Michael Pham², Caroyln Harvey³, Leroy W. Griffing² and Vivek Nagaraja², ¹Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ²Mayo Clinic, Scottsdale, AZ, ³Mayo Clinic, Phoenix, AZ
Background/Purpose: Calcinosis is a vexing manifestation in patients with systemic sclerosis (SSc) with a variable prevalence among cohorts. Up to 86% of calcinosis cases are…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].